SCHEMBL17812936

SCHEMBL17812936

CC(C)(C)OC(=O)[C@@H]1CC[C@@H](OC(=O)c2ccc([N+](=O)[O-])cc2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
PTPN2 P17706 1/20 0.47
PTPN1 P18031 1/20 0.47
MAPT P10636 4/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.46
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPC1 O15118 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
MMP2 P08253 1/20 0.38
ANPEP P15144 1/20 0.38
HTT P42858 1/20 0.38
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
ADRB3 P13945 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19566136 0.94 POLB (0.51) POLBSMN1; SMN2PTPN2PTPN1MAPT
SCHEMBL8607784 0.91 POLB (0.52) POLBSMN1; SMN2PTPN2PTPN1MAPT
SCHEMBL8646231 0.85 MMP2 (0.51) POLBSMN1; SMN2PTPN2PTPN1MAPT
SCHEMBL12140713 0.84 POLB (0.51) POLBSMN1; SMN2PTPN2PTPN1MAPT
SCHEMBL13495903 0.82 POLB (0.54) POLBSMN1; SMN2PTPN2PTPN1MAPT
SCHEMBL3248140 0.82 POLB (0.54) POLBSMN1; SMN2PTPN2PTPN1MAPT
SCHEMBL6802356 0.82 MAPT (0.59) POLBSMN1; SMN2PTPN2PTPN1MAPT
SCHEMBL6802352 0.82 MAPT (0.59) POLBSMN1; SMN2PTPN2PTPN1MAPT
SCHEMBL4894971 0.80 POLB (0.56) POLBSMN1; SMN2PTPN2PTPN1MAPT
SCHEMBL4894965 0.80 POLB (0.56) POLBSMN1; SMN2PTPN2PTPN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170320884-A1 HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed
US-20170320884-A1 HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed
WO-2016086358-A1 HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-06-09 WO disclosed
WO-2016089722-A1 HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320884-A1 HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR POLB 3987/4885SMN1; SMN2 2388/4885PTPN2 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.